Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Histologic Type × anlotinib × 1 year × Clear all

Sponsor

Conditions

Small Cell Lung Carcinoma 6 Carcinoma, Non-Small-Cell Lung 5 Thyroid Neoplasms 3 Sarcoma 3 Pancreatic Neoplasms 2 Gallbladder Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Cholangiocarcinoma 2 Breast Neoplasms 2 Whole-Brain Radiotherapy 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Proteinuria 1 Progression Free Survival(PFS) 1 Platinum-resistant Ovarian Cancer (PROC) 1 Lung Neoplasms 1 Limited Stage Small Cell Lung Cancer 1 Leiomyosarcoma 1 HER2-Negative Breast Cancer 1 Extensive Stage Lung Small Cell Cancer 1 Craniopharyngioma 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

fludarabine 4 Cisplatin 4 Pemetrexed 3 Cyclophosphamide 3 pralsetinib 2 pembrolizumab 2 fludarabine phosphate 2 durvalumab 2 cobimetinib 2 atezolizumab 2 Whole-Body Irradiation 2 Vemurafenib 2 Tacrolimus 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Paclitaxel 2 Nivolumab 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Busulfan 2 130-nm albumin-bound paclitaxel 2 trametinib 1 spartalizumab 1 ruxolitinib 1 repotrectinib 1 ponatinib 1 pertuzumab 1 gilteritinib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡